surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers surmount-1 trial tirzepatide obesity without

166 , 199207.e115 (2013)

DSIP promotes delta wave activity during deep sleep stages, enhancing the most restorative phase of sleep where physical recovery, immune function, and memory consolidation occur optimally

While renin-angiotensin system (RAS) and sodium glucose cotransporter 2 (SGLT2) inhibitors reduce CKD progression and cardiovascular risks, residual risks remain, especially with high albuminuria

Hence, it is essential to take your healthcare provider onboard before including any new supplement into your diet or making any kind of lifestyle alterations, especially when you are dealing with certain health conditions or are pregnant

This means it works similarlyby mimicking the GLP-1 hormone, which helps reduce appetite, slow digestion, and stabilize blood sugar levels

PMID: 29081890